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Available online 5 May 2016Background: There are reports of developmental and reproductive health effects associatedwith the widely used
biocide triclosan.
Objective: Apply the Navigation Guide systematic reviewmethodology to answer the question: Does exposure to
triclosan have adverse effects on human development or reproduction?
Methods:We applied the ﬁrst 3 steps of the Navigation Guidemethodology: 1) Specify a study question, 2) Select
the evidence, and 3) Rate quality and strength of the evidence. We developed a protocol, conducted a compre-
hensive search of the literature, and identiﬁed relevant studies using pre-speciﬁed criteria.We assessed the num-
ber and type of all relevant studies. We evaluated each included study for risk of bias and rated the quality and
strength of the evidence for the selected outcomes. We conducted a meta-analysis on a subset of suitable data.
Results:We found 4282 potentially relevant records, and 81 records met our inclusion criteria. Of the more than
100 endpoints identiﬁed by our search, we focused our evaluation on hormone concentration outcomes, which
had the largest human and non-human mammalian data set. Three human studies and 8 studies conducted in
rats reported thyroxine levels as outcomes. The rat data were amenable to meta-analysis. Because only one of
the human thyroxine studies quantiﬁed exposure, we did not conduct a meta-analysis of the human data.
Through meta-analysis of the data for rats, we estimated for prenatal exposure a 0.09% (95% CI:−0.20, 0.02) re-
duction in thyroxine concentration permg triclosan/kg-bw in fetal and young rats compared to control. For post-
natal exposurewe estimated a 0.31% (95%CI:−0.38,−0.23) reduction in thyroxine permg triclosan/kg-bw, also
compared to control. Overall, we found low to moderate risk of bias across the human studies and moderate to
high risk of bias across the non-human studies, and assigned a “moderate/low” quality rating to the body of
evidence for human thyroid hormone alterations and a “moderate” quality rating to the body of evidence for
non-human thyroid hormone alterations.
Conclusion: Based on this application of theNavigation Guide systematic reviewmethodology, we concluded that
there was “sufﬁcient” non-human evidence and “inadequate” human evidence of an association between triclo-
san exposure and thyroxine concentrations, and consequently, triclosan is “possibly toxic” to reproductive and
developmental health. Thyroid hormonedisruption is anupstream indicator of developmental toxicity. Addition-
al endpoints may be identiﬁed as being of equal or greater concern as other data are developed or evaluated.
© 2016 The Authors. Published by Elsevier Ltd. This is an open access article under the CC BY-NC-ND license
(http://creativecommons.org/licenses/by-nc-nd/4.0/).Keywords:
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Integration of the available scientiﬁc evidence to reach a strength-of-
evidence conclusion about chemical toxicity is fundamental to develop-
ing hazard assessments for regulatory action, clinical guidelines, and
safer alternatives to toxic chemicals. To this end, the Navigation Guide
systematic review methodology was developed by a working group in
2009 to provide a transparent, reproducible framework to evaluate
the quality and strength of evidence about the relationship betweenthe CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
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(Woodruff and Sutton, 2011). Beginning in 2011, the National Toxicology
Program (NTP) undertook a complementary effort to develop a frame-
work for systematic reviews in environmental health (Rooney et al.,
2014). In 2014 two reports by the National Academy of Sciences found
that such methods of evidence integration reﬂect the approach that the
U.S. Environmental Protection Agency (U.S. EPA) should adopt to deter-
mine whether environmental chemicals are harmful to human health
(National Research Council, 2014a; National Research Council, 2014b).
A report from the UK similarly recommended uptake of systematic
methods of evidence integration by relevant European Union agencies,
to increase transparency and decrease bias in regulatory rulemaking
(Whaley, 2013). Since 2012, the NTP has been actively building the
tools, expertise, and other infrastructure that will facilitate increased uti-
lization of systematic review methodologies (Rooney et al., 2014;
National Toxicology Program, 2015). The U.S. EPA has proposed steps to
begin to incorporate principles of systematic review into its Integrated
Risk Information System (IRIS) process (U.S. Environmental Protection
Agency, 2014; The National Academies, 2012). A 2014 case study
applying the Navigation Guide methodology to evaluate the human and
non-human evidence of perﬂuorooctanoic acid (PFOA) on fetal growth
demonstrated how the efforts under development by the NTP and con-
sideration by the U.S. EPA are achievable (Koustas et al., 2014; Johnson
et al., 2014; Lam et al., 2014; Woodruff and Sutton, 2014). The present
case study was intended as part of ongoing proof-of-concept and an
opportunity for the California Ofﬁce of Environmental Health Hazard
Assessment (OEHHA) to explore the Navigation Guide methodology
on a broader range of outcomes. This systematic review evaluates the
evidence for the effects of exposure to the widely-used biocide triclosan
on endpoints of developmental and/or male or female reproductive
toxicity.
Triclosan, or 2,4,4′-trichloro-2′-hydroxydiphenyl ether, is a synthet-
ic, broad-spectrum anti-microbial agent developed over 50 years ago
and introduced as a surgical scrub (Cooney, 2010). In 2013, there
were 2000 antimicrobial consumer products, including soaps and
other personal care products, dental products, clothing, paints, plastics
and children's toys (Halden, 2014). A 2000 survey found that 76% of
U.S. liquid soaps and 29% of bar soaps contained triclosan or an alterna-
tive antimicrobial triclocarban (Perencevich et al., 2001).
The FDAhas the authority to regulate triclosanwhen used in person-
al care products and medical devices. As the FDA has not ﬁnalized its
1974 draft topical antimicrobial drug products Over-the-Counter Drug
Monograph, triclosan is currently unregulated in personal care products
(U.S. Food and Drug Administration, 2013). With intent to ﬁnalize the
Monograph, the FDA proposed a new rule in 2013 that would require
manufacturers to provide safety data and data that demonstrates the
clinical beneﬁt of using antibacterial soaps over plain soap and water
(U.S. Food and Drug Administration, 2013). Pesticidal uses of triclosan
come under the regulatory authority of U.S. EPA (U.S. EPA, 2015).
Exposure to triclosan is widespread in the U.S. population
(Adolfsson-Erici et al., 2002; Calafat et al., 2008; Wilding et al., 2009;
Wolff et al., 2007). There is also growing concern over triclosan's possi-
ble effects on public health, including direct health effects, e.g., skin irri-
tation (Robertshaw and Leppard, 2007; Schena et al., 2008), endocrine
disruption and associated reproductive effects as observed in animal ex-
periments (Foran et al., 2000; Matsumura et al., 2005; Veldhoen et al.,
2007; Stoker et al., 2010) and human studies (Wolff et al., 2010; Chen
et al., 2013; Koeppe et al., 2013), and indirect effects, i.e., antibiotic
resistance (Aiello et al., 2007).
This is the ﬁrst systematic review of the human and animal evidence
linking exposure to triclosan to adverse reproductive or developmental
health endpoints. Past reviews of triclosan were expert-based narrative
reviews, not systematic reviews, and/or primarily focused on assessing
the risk of using personal care products containing triclosan, using
exposure estimates based on certain concentrations of triclosan in
the products (Rodricks et al., 2010; SCCS. Scientiﬁc Committee onConsumer Safety, 2011; Witorsch, 2014). In contrast, we did not esti-
mate exposure or assess risk in the present review;we evaluated the ev-
idence of the chemical's toxicity (i.e., hazard).
Based on the presence of triclosan in wide-ranging consumer prod-
ucts, the environment, and humans, and potential for human health ef-
fects, we applied the Navigation Guide systematic review methodology
to evaluate the strength of the evidence relating triclosan exposure to
developmental or reproductive health effects.
2. Methods
The Navigation Guide is based on best practices in evaluation of clin-
ical evidence and adapts the evidence-basedmedicinemethodology de-
veloped by Cochrane and the Grading of Recommendations Assessment
Development and Evaluation (GRADE), tested and evaluated since
the 1990s (Guyatt et al., 2011; Balshem et al., 2011).We assembled a
team of reviewers with expertise in toxicology, epidemiology,
environmental health, biology, statistics and systematic review, and de-
veloped a pre-speciﬁed protocol for conducting the systematic review
(Johnson et al., 2013). Each of the protocol steps are described
below and the protocol is available at http://prhe.ucsf.edu/prhe/pdfs/
Triclosan%20Protocol.pdf.
2.1. Specify the study question
Our objective was to answer the question: “Does exposure to triclo-
san have adverse effects on human development or reproduction?”We
developed a “Participants,” “Exposure,” “Comparator” and “Outcomes”
(PECO) statement, which is used as an aid to developing a strategy for
answering the study question (Higgins and Green, 2011). Our PECO
statement was:
2.1.1. Participants
Humans or animals (whole organism studied during the
reproductive or developmental time period, tissue, organ, cell line or
components), or computer models of humans or animals.
2.1.2. Exposure
For developmental effects, we included one or more exposures to
triclosan, by any route, which occurred during the following periods:
pre-conception (exposure of either or both parents or, if relevant, pre-
ceding generations), prenatal (exposure of pregnant female and/or di-
rectly of fetus), or postnatal (until the time of sexual maturation).
For reproductive effects, we include one ormore exposures to triclo-
san at any time preceding assessment of reproductive outcome.
2.1.3. Comparators
Comparable populations or subjects (human, non-human, tissues,
organs, cell lines or components) exposed to vehicle-only treatment
or lower levels of triclosan than the more highly exposed subjects.
2.1.4. Outcomes
Reproductive effects: alterations in hormone levels; effects on male
or female gametes (production, maturation, or transport), fertility, fe-
cundity, estrous cycles, menstrual cycles, endocrine function, sexual be-
havior, gestation, parturition, lactation, age at puberty or reproductive
senescence or menopause; pregnancy complications; increased preg-
nancy wastage; or alterations in size, morphology, or function of repro-
ductive organs.
Developmental effects: fetal loss or resorption, stillbirth, neonatal or
subsequent mortality, alterations in sex ratio, altered fetal or postnatal
growth, structural malformations and variations, altered gestation
length, functional deﬁcits such as alterations in behavior, andmorbidity.
In addition to effects of prenatal exposure during all or any part of ges-
tation, developmental toxicity can result from: 1) pre-conception expo-
sure of parental or previous generations causing genetic mutation or
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spring, and 2) postnatal exposure when the developing offspring is
more susceptible to adverse effects of the toxic agent than is themature
animal: Qualitatively (effect not seen in similarly-exposed adults);
Quantitatively (effect seen at lower doses, or to a greater extent, in im-
mature organisms than in adults).
2.2. Select the evidence
2.2.1. Search methods
Our search was not limited by language or publication date. We
searched several online databases (PubMed, ISI Web of Science, Biosis
Previews, Embase and Toxline) on June 5, 2013 using the search terms
in Table S1 (Supplemental material). We used the following databases
to compile synonyms for triclosan: Medical Subject Headings (MeSH),
PubChem, Sigma-Aldrich, and ChemSpider (http://pubchem.ncbi.nlm.
nih.gov/summary/summary.cgi?q=nama&cid=5564; http://www.
sigmaaldrich.com/catalog/product/sigma/72779?lang=en&region=
US; http://www.chemspider.com/Chemical-Structure.5363.html). We
identiﬁed additional synonyms from several reviews and original re-
search articles on triclosan (Rodricks et al., 2010; Dann and Hontela,
2011; James et al., 2010; Fang et al., 2010; Anon., 2011; Ciba Specialty
Chemicals Corporation, 2004). We combined “triclosan” and its syno-
nyms in a Boolean search using the “OR” statement. We searched for
terms in titles and abstracts (using the [tiab] function in PubMed,
topic search in Web of Science and Biosis Previews; “ti,ab.” function in
Embase) or in MeSH headings (using the [mh] function in PubMed).
We searched additional toxicological websites (June 17–25, 2013); the
speciﬁc databases searched are provided in the Supplemental material
(Table S2). We also hand-searched the reference lists of all included
studies and used Web of Science to search for articles that cited the in-
cluded studies.
2.2.2. Study selection criteria
We selected studies where triclosan was administered, measured
or estimated and associations with developmental or reproductive
outcomes were evaluated using a customized, structured form in
DistillerSR (Evidence Partners; available at: http://www.systematic-
review.net). Two of 5 possible reviewers (DA, RB, MC, AK, HV) indepen-
dently conducted a title and abstract review of each reference from the
literature search results to determine eligibility based on the criteria for
inclusion. References not excluded based on the title and abstract were
screened through full-text review by the title/abstract reviewers and a
sixth reviewer (EK). An additional reviewer (PJ) screened 5% of the
titles/abstracts and full-texts for quality assurance. In the case of
differences between reviewers, the initial reviewers discussed the dis-
crepancy and consulted another reviewer (PJ) if necessary to decide
whether to exclude the reference.
We excluded studies if: 1. the report did not contain original data; 2.
there was no triclosan exposure prior to the assessment of effect; 3. no
developmental or reproductive outcomes were reported; or 4. there
was no comparator (control group or exposure range comparison).
2.2.3. Data collection and management
Weassessed the number of studies resulting fromour search and the
number of health outcomes. Two authors (DA, AK for human studies;
EK, HV for non-human studies) independently extracted data and de-
tails of study design and outcomemeasures (see Supplemental materi-
al, Data extraction ﬁelds) from all included human and non-human
mammalian articles into a Microsoft Access (2010) database.
We contacted an author of each included non-human mammalian
study to request raw data from all relevant ﬁgures where data were
only presented in graphical form and to obtain additional data which
were pertinent to our study question but were missing or ambiguous.
We contacted authors of human and non-human mammalian studieswhen the information provided in the study was unclear with respect
to rating risk of bias domains.
2.3. Statistical analyses
We assessed study characteristics of included studies to determine
suitability for use in a meta-analysis. We reported outcome measures
and their standard errors (reported in the study or calculated from re-
ported standard deviations and sample sizes) as a percentage normal-
ized to the respective control groups, to have the same metric across
studies. When meta-analysis was possible, we used a two-step model-
ing approach as described previously (Koustas et al., 2014). In the ﬁrst
step we analyzed each dataset separately using a linear mixed effects
model and obtained a slope estimate of the dose–response effect and as-
sociated standard error. In the second step we combined the slope and
standard error estimate from each dataset using a random effects
model, producing an estimate of the overall mean change in thyroxine
concentration per 1-unit increase in triclosan dose (mg/kg-bw-day), ac-
counting for within- and between-study variability. We used Stata SE
(Version 10: StataCorp LP, College Station, Texas, USA) to perform
both steps in the analysis; we used the metareg function for step one
and themetan function for step two. We evaluated statistical heteroge-
neity across study estimates in themeta-analysis using Cochran's Q sta-
tistic with p ≤ 0.05 as our cut-off for statistical signiﬁcance and I2,
(Higgins and Green, 2011) as previously described (Koustas et al.,
2014; Johnson et al., 2014).
2.4. Rate the quality and strength of the evidence
We rated the quality and strength of the evidence according to the
following steps: 1)We assessed the “risk of bias” (deﬁned as study char-
acteristics capable of introducing systematic error in the magnitude or
direction of the results; Higgins and Green, 2011) for each included
study; 2) we rated the quality of the evidence across studies; and
3) we rated the strength, or certainty, of the evidence across studies.
2.4.1. Assessing the risk of bias for each included study
We assessed risk of bias for the included human and non-human
studies using revised instruments (Supplemental material, Instructions
for making risk of bias determinations) that were previously developed
for human and animal evidence (Koustas et al., 2014; Johnson et al.,
2014), based on existing guidance from the Cochrane Collaboration's
“Risk of Bias” tool and the Agency for Healthcare Research and Quality's
(AHRQ) criteria that address selection bias and confounding, perfor-
mance bias, attrition bias, detection bias, and reporting bias (Higgins
and Green, 2011; Viswanathan et al., 2012). Because our body of
human evidence included a study that was a subset of a randomized
clinical trial (Cullinan et al., 2012), rather than evaluate that study for
“baseline differences” as for the other observational studies,we evaluat-
ed that study for two different risk of bias domains which were part
of our “Non-human experimental studies” risk of bias instrument
(Supplementalmaterial).We also included ﬁnancial conﬂicts of interest
as a potential source of bias based on data from studies on pharmacolog-
ical treatments showing evidence of bias associatedwith funding source
(Lundh et al., 2012; Krauth et al., 2013).
We assigned each risk of bias domain as “low risk of bias,” “probably
low risk of bias,” “probably high risk of bias,” “high risk of bias,” or “not
applicable” (risk of bias area not applicable to study) according to spe-
ciﬁc criteria as described in our risk of bias instruments (Supplemental
material, Instructions for making risk of bias determinations). Review
authors (DA, PJ, AK for human studies; EK, HV for non-human studies)
independently recorded risk of bias determinations for each included
study and discussed any discrepancies until consensus was reached.
We determined the important potential confounders or effect mod-
iﬁers by which to determine risk of bias for the human studies by
searching the included studies, the cited references and other known
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Health andNutrition Examination Survey (NHANES), for evidence of as-
sociations between potential confounders and triclosan exposure and
the outcomes under study. Because age and body mass index (BMI)
are associated with triclosan exposure and with thyroid hormone con-
centrations (Calafat et al., 2008; Chen et al., 2013; Lankester et al.,
2013; Knudsen et al., 2005; Hollowell et al., n.d.), we assigned studies
“low risk” of bias under the confounding domain if they accounted for
potential confounding by age and BMI. Because triclosan is relatively
non-persistent (half-life b 24 h), there is uncertainty in relying on a sin-
gle urine measurement of triclosan to assess longer term exposure, and
this reliance assumes that exposure is consistent over time. However,
there is some evidence that a single urine triclosanmeasurement is a rea-
sonably reliable estimate of exposure over time (Spearman correlation
coefﬁcient for measurements 3 months apart = 0.50) (Teitelbaum
et al., 2008; Bertelsen et al., 2014). We considered this uncertainty and
assumption in relation to each outcome in evaluating risk of bias under
the exposure assessment domain for observational studies.2.4.2. Rating the quality of evidence across studies
We separately rated the overall quality of the bodies of human and
non-human evidence as “high,” “moderate” or “low.” The Navigation
Guide follows the approach established by the GRADE method; i.e., we
determined the ﬁnal rating by ﬁrst assigning a pre-speciﬁed quality
rating to the bodies of evidence and then considered adjustments
(“downgrades” or “upgrades”) to the quality rating based on the charac-
teristics of the included studies (Balshem et al., 2011). The quality
ratings are not additive scores but serve as qualitative guidance in
assessing the overall quality of evidence. GRADE guidelines are used to
evaluate clinical interventions and assign an initial rating of “high” to
bodies of evidence consisting of experimental human studies and an ini-
tial rating of “low” quality to observational studies (Balshem et al.,
2011). We recognize, however, that not all observational studies are of
low quality (Viswanathan et al., 2012; U.S. Environmental Protection
Agency, 1996; International Agency for Research on Cancer, 2006) and
that decisions in the context of environmental health may rely heavily
on human observational data (Woodruff and Sutton, 2011). We there-
fore assigned an initial rating of “moderate” quality to the body of
human evidence, which primarily consisted of observational studies,
in consideration of the value and limitations of observational data in
assessing associations between exposure and health outcomes in envi-
ronmental health (Woodruff and Sutton, 2014). We assigned an initial
rating of “high” quality to the experimental animal data, comparable
to human randomized controlled trials and consistent with GRADE
guidelines for experimental human studies, i.e. randomized controlled
trials (Guyatt et al., 2011).
We assessed the overall bodies of human and non-human evi-
dence for downgrading and upgrading the pre-speciﬁed quality rat-
ings based on speciﬁc factors (Supplemental material, Table S2).
These factors, based on GRADE guidelines (Balshem et al., 2011),
were risk of bias, indirectness, inconsistency, imprecision, publica-
tion bias, large magnitude of effect, dose response and whether con-
founding minimizes the effect. Possible ratings were 0 (no change
from initial quality rating), −1 (1 level downgrade) or – 2 (2 level
downgrade); +1 (1 level upgrade) or +2 (2 level upgrade). We
each independently evaluated the quality of the evidence and then
compared our ratings and rationale for each quality factor. We
discussed our ratings as a group and recorded our rationale. Consis-
tent with GRADE, we did not automatically add together the ratings
for each downgrade and upgrade factor to create a score, e.g., a (−1)
downgrade for each of 2 factors does not necessarily translate into a
(−2) downgrade overall. Also consistent with GRADE, upgrades and
downgrades were made only when there was compelling evidence
to do so. We used judgment to decide the weight of each downgrade
or upgrade in the ﬁnal overall quality rating.2.4.3. Rating the strength of the evidence across studies
We rated the overall strength of each body of evidence based on 4
considerations: (1) Quality of body of evidence (i.e., the rating from
the previous step); (2) Direction of effect; (3) Conﬁdence in effect (like-
lihood that a new study would change our conclusion); and (4) Other
compelling attributes of the data that may inﬂuence certainty. We used
these considerations to assign the overall strength rating, according to
the deﬁnitions speciﬁed in the Navigation Guide for “sufﬁcient evidence
of toxicity,” “limited evidence of toxicity,” “inadequate evidence of toxic-
ity,” or “evidence of lack of toxicity” (Supplemental material, Tables S3
and S4), which are based on categories used by the International Agency
for Research on Cancer (IARC). The Navigation Guide uses criteria and
considerations used by IARC, the U.S. Preventive Services Task Force,
and U.S. EPA for the type of evidence considered for each of its strength
of evidence categories (U.S. Environmental Protection Agency, 1991;
U.S. Environmental Protection Agency, 1996; International Agency for
Research on Cancer, 2006; Sawaya et al., 2007). We each evaluated the
strength of the evidence independently. We then convened to compare
evaluations, resolve discrepancies by discussion, and record the collec-
tive rationale for decisions. We integrated the human and non-human
evidence streams as speciﬁed in the Navigation Guide methodology, a
process adapted from IARC's method which results in a single concise
statement of health hazard (Woodruff and Sutton, 2011; International
Agency for Research on Cancer, 2006). The result is one of ﬁve possible
statements on the impact of triclosan on reproductive or developmental
health: 1. known to be toxic; 2. probably toxic; 3. possibly toxic; 4. un-
classiﬁable; or 5. probably not toxic (Fig. S1).3. Results
3.1. Included studies
Our search retrieved a total of 9485 records. After eliminating dupli-
cates, 4282 unique records remained. By applying the speciﬁc
predeﬁned exclusion criteria, we excluded themajority of the irrelevant
references (4034 abstracts excluded out of 4282 total) in under 18 h av-
erage for each reviewer. The remaining irrelevant references were ex-
cluded in under 6 h average during full-text screening. After
application of the exclusion criteria, 81 articles remained: 24 inverte-
brate studies, 16 in vitro studies, 14 ﬁsh studies, 8 amphibian studies,
13 rodent studies, and 6 human studies (Fig. 1 and list in Supplemental
material). In addition to the wide range of, and sparse data for, non-
mammalian outcome measures, we did not have a developed method
to assess the strength of the evidence for reproductive and developmen-
tal toxicity for these types of studies. Therefore, we limited our analysis
to the mammalian (human and rodent) studies (Fig. 1; Tables S27 and
S28). We also found numerous outcome measures (over 100 unique
outcomes, including various endpoints at the cellular level) within
the 13 rodent studies, with relatively sparse data for each outcome.
However, most of the 6 human and 13 rodent studies focused on hor-
mone modulation as an outcome measure, and thus we focused our
analysis on that outcome. Thyroid hormone disruption is an upstream
indicator of developmental toxicity (Miller et al., 2009; Woodruff
et al., 2008; Crofton, 2008; Wise et al., 2012).
Three of 6 human studies reported associations between triclosan
and thyroid hormones. The human studies spanned the years 2010 to
2013, had different study designs and ranged from 12 to 1831 study
subjects from differing populations (Table 1). Eight of 13 rodent studies
provided data on hormone levels following prenatal, prenatal plus post-
natal, or postnatal-only exposure to triclosan (Table 2). Our search iden-
tiﬁed a rat study by Crofton et al. (2007), but because those data were
included in the study by Paul et al. (2010a), we did not include the
data reported in the Crofton et al. publication. We considered only the
3 human and 8 rat hormone studies in rating the quality and strength
of the evidence.
Fig. 1. Flowchart of the study-selection process.
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We assigned “low” or “probably low” risk of bias designations to the
majority of the domains for the 3 included human hormone studies
(Fig. 2). We assigned “probably high” risk of bias designations to the
majority of the 8 included rat studies, particularly for the “allocation
concealment” and “blinding” domains (Fig. 3). Additional detail on
individual study characteristics and risk of bias designations is in the
Supplemental material.3.3. Data analysis
3.3.1. Human data
Because there were few studies and dissimilar types of data, we
could not conduct a meta-analysis of the human data. Although 3
human studies measured thyroid hormones, only one quantiﬁedTable 1
Human studies reporting hormone concentration outcome (N= 3).
Study Study design Population Loc
Koeppe et al. (2013) Cross sectional U.S. population (NHANES) Un
Cullinan et al. (2012) Randomized controlled trial Subset of cardiovascular and
periodontal study cohort
Un
Allmyr et al. (2009) Case-crossover experiment Adults Swexposure (urinary triclosan from NHANES) (Koeppe et al., 2013),
while in the other 2 of these studies, the exposurewas use of toothpaste
containing triclosan, and was not measured (Viswanathan et al., 2012;
Paul et al., 2012).
3.3.2. Non-human mammalian data
Of 8 included rat hormone studies, 6 were amenable to meta-
analysis for the outcome thyroxine concentration: 3 studies with 4
datasets where triclosan was administered during gestation, and from
4 studies with 6 datasets where triclosan was administered directly to
the offspring during the postnatal developmental period or in both the
pre- and postnatal periods.
The thyroxine studies had the following characteristics:
• Species: rat.
• Route of exposure: oral gavage.
• Outcome measurement: thyroxine concentration.ation Outcome measures n Exposure assessment
ited States Serum free T3
Serum total T3
Serum free T4
Serum total T4
Serum TSH
Serum thyroglobulin
1831 Urinary triclosan
ited States Serum TSH
Serum free T4
Serum free T3
Antithyroglobulin antibody
Antithyroid peroxidase antibody
132 Use of toothpaste containing
0.3% triclosan vs. placebo
eden Plasma 4b-hydroxycholesterol
Plasma free T3
Plasma free T4
Plasma TSH
12 Use of toothpaste containing
0.3% triclosan
Table 2
Summary of studies of triclosan and rodent hormone concentrations (N= 8 studies and 10 data sets).
Study Species Strain Route of
administration
Time of
administration
Time of assessment Doses
testeda
Total
numberb
Hormone concentration outcomec,d
Paul et al. (2012) Rat Long–Evans Oral gavage GD6–PND21 GD20 10–300 54 litters Total T4e
GD20 54 Total T4 (dams)
PND22 95 Total T4 (dams)
Stoker et al. (2010) Rat Wistar Oral gavage PND19–21 PND21 1.18–75 48f Total T4e; Free T4
PND22–42 PND42 9.375–150 50f Total T4e; Free T4; TSH
Paul et al. (2010b) Rat Long–Evans Oral gavage GD6–PND22 PND4 30–300 34 littersg Total T4
PND14 36 littersh Total T4
PND21 37 littersh Total T4e
Rodriguez and
Sanchez (2010)
Rat Wistar Drinking water 8 days prior to
mating–PND21
GD5, GD10, GD15,
GD20, PND5, PND10,
PND15, PND20
1–50 32 Total T3 (dams); Total T4 (dams)
Paul et al. (2010b)k Rat Long–Evans Oral gavage PND27–29 (range of
age at treatment)
for 4 days
PND31–33 (range of
age at assessment)
10–1000 120 Total T4e,i
30–1000 40 Total T3i; TSHi
Zorrilla et al. (2009) Rat Wistar Oral gavage PND23–53 PND53 3–300 71f Total T4e,i; Total T3; TSH; Total
testosterone; Total androstenedione
Kumar et al. (2009) Rat Wistar Oral gavage Approx. PN week 10
for 60 days
Approx. PND130 20 16 Testosterone; Androstenedione;
Pregnenolone; Follicle stimulating
hormone; Luteinizing hormone
Axelstad et al. (2013) Rat Wistar Oral gavage GD7–PND16 GD15 75–300 32 Total T4 (dams)
PND16 75–300 32 Total T4 (dams)
32 littersj Total T4 (males and females)e
PND3–16 PND16 50–150 5 litters
(38 animals)j
Total T4 (males and females)e
(GD) = gestational day.
(PND) = postnatal day.
(T4) = thyroxine.
(T3) = triiodothyronine.
(TSH) = thyroid-stimulating hormone.
a mg/kg-bw/day. A control group was included for each study.
b Number of animals, unless otherwise speciﬁed. See Supplemental study characteristics tables for number of animals per dose groups.
c Serum measurements presented, unless otherwise speciﬁed.
d Outcomes for gestational exposures are for offspring, unless otherwise noted.
e Outcome included in meta-analysis.
f Exact numbers analyzed not provided; value represents estimate based on numbers allocated.
g Samples collected from culled pups from each litter (to normalize litter size to 8) and pooled for analysis.
h One male and one female selected from each litter and sample pooled for analysis.
i Absolute and % of control values presented.
j Sampleswere pooledwithin litter (by sex). Nursing litterswere culled to normalize litter size to 8 but not cross-fostered. Two litterswere assigned to each of 3 groups. One of 2 control
dams rejected litter, leaving 1 genetically homogeneous control litter. The control litter was reported to have higher T4 levels compared to historical laboratory controls.
k Our search identiﬁed a study by Crofton et al. (2007), but because those datawere included in the study by Paul et al. (2010b), we did not include the data reported in the Crofton et al.
publication.
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times measured in days.
We reported thyroxine concentrations and their standard errors, as a
percentage normalized to the concentration in the control group. We
were unable to obtain raw data from studies that already reported nor-
malized concentrations. The result was an estimate of the overall mean
change in thyroxine concentration for a 1-unit increase in triclosan
(mg/kg-bw-day), accounting for within- and between-study variability.
We used only data from triclosan doses equal to or below 300 mg/kg-
body weight (bw)-day. The dose was limited to focus on effects at
lower tested doses and to minimize adverse impacts from responses
at higher doses (such as litter loss) on the overall estimate and to ac-
count for themodel assumptions of linearity. Onedose groupwas there-
fore omitted: 1000 mg/kg-bw-day (Paul et al., 2010a).
Administration of triclosan to dams during gestationwas not associ-
ated with a consistent dose response in the offspring; however, one
study (Paul et al., 2012) evaluated thyroid hormone levels during gesta-
tion and showed a signiﬁcant dose–response in fetuses (Fig. 4). The
overall pooled meta-analysis estimate was a 0.09% reduction in thyrox-
ine per mg/kg unit increase in triclosan (95% CI −0.20 to 0.02; I2 =
22.8%; Fig. 4B). In contrast, there was a clear dose response for triclosan
administered during the postnatal developmental time period (Fig. 5A)
and the overall pooled meta-analysis estimate was a 0.31% reduction inthyroxine per mg/kg unit increase in triclosan (95% CI−0.38 to−0.23;
I2 = 61.5%; Fig. 5B). For other hormones (4 studies) we generally ob-
served a trend towards a reduction in concentration, although there
were limited data on each hormone and conﬁdence intervals mostly
overlapped (Supplemental material, Fig. S2).
3.4. Rating the quality and strength of the bodies of evidence for hormone
modulation
3.4.1. Human evidence
We rated the overall quality of the human evidence “low to
moderate.” We rated the ﬁnal overall strength of the human evi-
dence “inadequate” (Table 3). Our rating of “inadequate” human ev-
idence was based on insufﬁcient evidence to assess the association
between triclosan and human thyroid hormone concentrations.
There were few studies (2 small studies and 1 large study) with in-
consistent ﬁndings.
3.4.2 Non-human mammalian evidence.
Each factor considered in rating the overall quality of the non-
humanmammalian (rat) hormonal evidence was consistent among re-
viewers except for “risk of bias” where 9 reviewers rated (−1); 2 re-
viewers (0); and 1 reviewer (0/−1) (Table 4). Ultimately we reached
consensus agreement to downgrade one level (to “moderate” quality)
based on our concerns about risk of bias, as we had rated “probably
Fig. 2. Summary of risk of bias graphs for individual human studies. Reviewauthors' judgments (low, probably low, probably high, andhigh risk) of bias for each risk of bias domain for each
included human study (n= 3). The risk of bias results did not differ according to different speciﬁc outcome measures within the studies, and therefore results are presented by study.
Cullinan et al. was a subset of a randomized controlled trial and was therefore evaluated under the “Sequence generation” and “Allocation” risk of bias domains and received a “N/A”
(not applicable) rating under the “Baseline differences” domain. The other studies received a “N/A” rating under the “Sequence generation” and “Allocation” domains.
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concealment and blinding (Table 4). We also had consensus on the
ﬁnal overall strength of the rodent evidence (sufﬁcient), based on con-
sistency in the ﬁndings of the studies and the meta-analysis estimate
of reduced thyroxine concentrations in relation to postnatal triclosan
exposure (Table 4).
Based on our evaluation using the Navigation Guide criteria, we
concluded that there was “sufﬁcient” non-human evidence and “in-
adequate” human evidence of an association between triclosan ex-
posure and thyroxine concentrations. Consequently, we concluded
that triclosan is “possibly toxic” to reproductive and developmentalFig. 3. Summary of risk of bias graphs for individual animal studies. Review authors' judgments (
included animal study (n=8). Note Stoker et al. presents two experiments using two separate
separately. aStoker et al. pubertal assay cohort assessed free T4, total T4, and TSH. bStoker et alhealth, based on the Navigation Guide evidence integration step
(Fig. S1).4. Discussion
We applied the Navigation Guide systematic review method to as-
sess whether exposure to triclosan has adverse effects on human devel-
opment or reproduction and found that triclosan is “possibly toxic” to
reproductive and developmental health, based on its adverse impacts
on the thyroid hormone thyroxine. Thyroid hormone disruption is anlow, probably low, probably high, andhigh risk) of bias for each risk of bias domain for each
cohorts (pubertal assay and uterotrophic assay); each cohort was evaluated for risk of bias
. uterotrophic assay cohort assess free T4 and total T4.
Fig. 4. Prenatal triclosan and thyroxine. A. Prenatal triclosan administration and thyroxine concentration as a percentage of the control group for doses up to 300 mg/kg/day. B. Prenatal
beta-estimates for dose response and the random effects meta-analysis estimate. The vertical gray bar in A represents the line of no effect (the control group normalized to 100%);
horizontal error bars represent 95% conﬁdence intervals; in B, symbol sizes represent the log of the weight in the meta-analysis.
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Woodruff et al., 2008; Crofton, 2008; Wise et al., 2012).
One of the goals of this review and other case studies of applying the
Navigation Guide methodology (Koustas et al., 2014; Johnson et al.,
2014; Lam et al., 2014; Vesterinen et al., 2014) was to develop proof
of concept of the use of improved methods of evidence integration in
environmental health. Such an incremental methods testing approach
has been successful in clinical medicine in developing an empiricalbasis for evidence-basedmedicine (Higgins and Green, 2011). The rela-
tively few human studies in the triclosan case study revealed points of
methodological consistency and inconsistency between the Navigation
Guide and other methods of evidence integration related to how the
terminology “possibly toxic” and “probably toxic” mapped to the
human and non-human evidence.
Our overall quality rating system for non-human evidence was
consistent with approaches adopted by the U.S. EPA for carcinogens
Fig. 5. Postnatal triclosan and thyroxine. A. Postnatal triclosan administration and thyroxine concentration as a percentage of the control group for doses up to 300mg/kg/day. B. Postnatal
beta-estimates for dose response and the random effects meta-analysis estimate. The vertical gray bar in A represents the line of no effect (the control group normalized to 100%);
horizontal error bars represent 95% conﬁdence intervals; in B, symbol sizes represent the log of the weight in the meta-analysis.
724 P.I. Johnson et al. / Environment International 92–93 (2016) 716–728and in the NTP-OHAT method in that it allowed for a ﬁnding of
“sufﬁcient” evidence based on positive ﬁndings in multiple studies or
a single appropriate study in a single species (National Research
Council, 2014b; Woodruff et al., 2008). However, the structure of our
evidence integration table, modeled after the IARC evidence integration
table for cancer (International Agency for Research on Cancer,
2006) does not align with U.S. EPA and NTP-OHAT when there was“insufﬁcient” human evidence. As adapted from IARC's preamble
(International Agency for Research on Cancer, 2006), in the absence of
consideration of mechanistic data, the Navigation Guide evidence inte-
gration step requires both “limited” human and “sufﬁcient” non-
human evidence of toxicity in order for a chemical to be found to be
“probably toxic” (Fig. S1). Current practice in U.S. EPA assessments of
non-cancer health outcomes (Miller et al., 2009; Woodruff et al.,
Table 3
Summary of rating quality and strength of the human hormonal evidence.
Category Downgrades Rationale
Risk of bias Eight (0); Four (−1) Two of the three studies, one large and one small, had “low” or “probably low” risk of bias for all domains.
However, some authors were more concerned about the potential risk of bias in the exposure assessment.
Indirectness Six (0): Six (−1) One study (Cullinan et al.) is of an older age group not representative of reproductive age where thyroid is
a developmental or reproductive concern; Cullinan et al. exposure assessment by toothpaste use only is
indirect. The concerns about this one study did not warrant a downgrade for some authors; but for some
the concern, particularly for indirect exposure assessment, warranted a downgrade.
Inconsistency Twelve (0) The results of the 3 studies were consistent.
Imprecision Twelve (0) Although the Koeppe et al. study had some wide conﬁdence intervals, most conﬁdence intervals were
sufﬁciently narrow.
Publication bias Twelve (0) There was variability in study size and there was a larger study (Koeppe et al.) showing no effect for some
outcomes. A comprehensive literature search did not identify studies with conﬂicting results. There were
not enough studies to utilize funnel plot analyses to assess publication bias.
Upgrades
Large magnitude of effect Twelve (0) All of the studies found null or minimal effects only.
Dose–response Eleven (0); One (+1) Most reviewers found minimal to no evidence of a dose–response gradient. One reviewer downgraded
based on a statistically insigniﬁcant dose–response gradient.
Confounding minimizes effect Twelve (0) There was no evidence that residual confounding inﬂuenced results.
Overall quality of evidence
(initial rating is “Moderate”)
Seven (Moderate); Five (Low)
Overall strength of evidence Inadequate The available evidence is insufﬁcient to assess effects of the exposure. Evidence is insufﬁcient because of:
the limited number or size of studies, low quality of individual studies, or inconsistency of ﬁndings across
individual studies. More information may allow an assessment of effects.
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human evidence to reach a comparable strength of evidence conclusion
(National Research Council, 2014b). In the NTP-OHAT method, a
chemical can be found to have a “presumed” hazard based on a combi-
nation of a “high” level of evidence in non-human studies and a “low,”
(equivalent to Navigation Guide “inadequate”), or “moderate” level of
evidence in human studies (National Research Council, 2014b;
National Toxicology Program, 2015) For future cases, we intend to re-
vise the Navigation Guide method for evidence integration to better
align with the labeling of the NTP-OHAT method (Rooney et al., 2014)
and current practices at the U.S. EPA, such that “probably toxic,”which
more closely maps to “presumed,” is reachable with strong non-
human evidence.
This case study demonstrates that all conclusions in environmental
health about a chemical's toxicity are limited by the available data. Of
the few human studies on triclosan, even fewer presented results
for the same outcome. For the non-human mammalian evidence,
we found studies conducted at various stages of development and
reporting over 100 unique outcome measures. For many endpoints,
the data were too limited to assess and most data were not conducive
to combining into meta-analysis. While conducting a meta-analysis is
not an essential component of hazard or risk assessment, it can be a use-
ful tool for synthesizing data. We narrowed the ﬁnal analysis to theTable 4
Summary of rating quality and strength of the non-human mammalian hormonal evidence.
Category Downgrades Rationale
Risk of bias Nine (−1); Two (0);
One (0/−1)
(−1): There was
risk of bias does n
high” risk, rather
Indirectness Twelve (0) Animal changes (
relevant to huma
Inconsistency Twelve (0) There was not sub
consistency betw
Imprecision Twelve (0) The conﬁdence in
Publication bias Twelve (0) There were not en
conducted a comp
include null ﬁndin
On this basis we d
Overall quality of evidence
(initial rating is “High”)
Moderate We downgraded
Overall strength of evidence Sufﬁcient We found sufﬁcie
reduced thyroxinhealth outcome with the most data, which may not equate with the
most sensitive health outcome or represent the best method of focusing
an investigation. Our results were primarily based on postnatal effects
in the non-human mammalian literature, as only one of the studies
evaluated effects on thyroid hormones during gestation. This is a chal-
lenge as previous literature ﬁnds that thyroid hormone levels during
gestation is an indicator of future neurodevelopment (Wise et al.,
2012; Morreale, 2001; Mastorakos et al., 2007). Our ﬁndings also illus-
trate a strength of systematic reviews in that the method identiﬁes re-
search gaps which can inform how scarce research funding could be
most efﬁciently and effectively targeted to answer a policy relevant
question. A complete list of relevant studies is included in the
Supplemental information and could be a starting point for identifying
where research could be directed to strengthening the evidence base.
This was the ﬁrst systematic review of the human and non-human
mammalian evidence for triclosan and reproductive and developmental
effects. One of the main strengths of systematic reviews is that the
criteria and rationale for judgements and decisions are transparently
documented. A different set of authors could presumably arrive at a dif-
ferent conclusion, but with this thorough documentation, the review is
reproducible and the reader can understand what led to the difference.
The present review elucidates the potential hazard of triclosan and
does not estimate exposure or conduct a quantitative risk assessment.“probably high” risk of bias across several domains; (0): Concern about overall
ot rise to the level of a downgrade; (0/−1): Most of the studies have “probably
than “high risk,” and this was mostly due to unknown information about the studies.
in rodents) are reﬂective of what is seen in humans and the outcomes were directly
ns.
stantial heterogeneity in studies across postnatal dosing for thyroxine; lack of
een post- and prenatal dosing has a biological explanation.
tervals were not wide for the thyroxine studies or the meta-analysis.
ough studies to utilize funnel plot analyses to assess publication bias. However, we
rehensive search and found studies of variable sizes and funding sources. Studies
gs as well as positive ﬁndings from studies with high risk for conﬂict of interest.
id not downgrade for publication bias.
one level based on concerns about risk of bias.
nt evidence that exposure to triclosan alters hormone levels in rats, based on
e levels.
726 P.I. Johnson et al. / Environment International 92–93 (2016) 716–728This is a distinction from previous reviews and risk assessments that
appear to have reached conclusions differing from the current sys-
tematic review. Rodricks et al. concluded, based on estimates of a
benchmark dose level and human exposure, that triclosan in con-
sumer products is not expected to cause adverse effects (Rodricks
et al., 2010). The Colgate-Palmolive Company-sponsored narrative
review of endocrine disrupting activity of triclosan by Witorsch con-
cluded that personal care products containing triclosan do not pose a
risk of adverse effects from endocrine disruption (Witorsch, 2014).
While both the present review and theWitorsch review found insuf-
ﬁcient evidence in humans and evidence of a dose-dependent de-
crease in thyroxine in rats, our conclusions about the available
evidence differed from Witorsch for several reasons. First, our
criteria for reaching a decision about a chemical's toxicity were de-
ﬁned and stated before our review was undertaken. In our review
we had consensus on the ﬁnal overall strength of the rodent evi-
dence (sufﬁcient), based on consistency in the ﬁndings of the studies
and the meta-analysis estimate of reduced thyroxine concentrations
in relation to postnatal triclosan exposure (Tables 4 and S4). In con-
trast, the Witorsch narrative review had no predeﬁned criteria for
reaching its conclusion and ultimately discounted the rat ﬁndings
on thyroxine because: (1) related ﬁndings were not present for
other thyroid system endpoints, namely TSH, T3, thyroid histology
or thyroid weight; (2) rats were not considered a proven model sys-
tem for thyroid disruption; and (3) the mode of action for T4 disrup-
tionwas unknown and/or inconsistent.We did not require that these
three criteria be met in order to consider triclosan “possibly” toxic.
We base this on previous literature identifying that thyroid hormone
disruption, in particular thyroxine decrements, is an indicator of ad-
verse effects (Miller et al., 2009; Woodruff et al., 2008; Crofton,
2008; Wise et al., 2012). In short, having consistent disruption of
all thyroid system endpoints, in human studies (implicit if rats are
to be discounted), and a documented mode of action sets a very
high bar for demonstrating a chemical's toxicity. In addition, it is
not consistent with the broad range of evidence evaluations by au-
thoritative bodies such as U.S. EPA and IARC and is not necessary to
make determinations about hazard (e.g., the mechanism of smoking
is not known, but it is a carcinogen).
A second possible reason for the difference between our conclusion
that triclosan is “possibly toxic” versusWitorsch's “TCS does not present
a risk of endocrinedisruptivehealth effects throughexposure to person-
al care products” is that our review focuses on the potential hazard of
triclosan and does not estimate exposure or conduct a risk assessment.
Health Canada did not consider thyroid function in rats a critical effect
for risk characterization of triclosan in humans, although they acknowl-
edged the uncertainty in human relevance of triclosan-induced
hypothyroxemia and the lack of developmental neurotoxicity data for
triclosan (Health Canada, 2012). The European Union's Scientiﬁc Com-
mittee on Consumer Safety (SCCS) acknowledged differences between
rats and humans with respect to thyroid hormone physiology and reg-
ulation, and they did not use the acceptable level of exposure, derived
from rat studies, in assessing risk of thyroid hormone effects (SCCS.
Scientiﬁc Committee on Consumer Safety, 2011). The SCCS conducted
a risk assessment using exposure levels based on animal studies of
other endpoints (e.g., hematotoxicity, reproductive effects) and con-
cluded that triclosan is safe as used in some personal care products
but not safe when considering aggregate exposures or high exposures
resulting from the use of certain leave-on cosmetics such as body lotion
(SCCS. Scientiﬁc Committee on Consumer Safety, 2011). None of these
risk assessments included a systematic review of the reproductive and
developmental hazard before undertaking the risk assessment (SCCS.
Scientiﬁc Committee on Consumer Safety, 2011; Health Canada, 2012;
Paul et al., 2013).
Thyroid hormone disruption is concerning because even small re-
ductions in thyroxine in pregnant women can have adverse effects on
neurodevelopment of children (Miller et al., 2009; Woodruff et al.,2008; Wise et al., 2012; Ghassabian et al., 2014; Henrichs et al., 2010).
Because there is widespread exposure to triclosan, a ﬁnding that triclo-
san is “possibly toxic” has important public health implications.
Contrary to our previous systematic review of PFOA and fetal growth
(Koustas et al., 2014; Johnson et al., 2014) our efforts to obtain addition-
al unpublished information by contacting study authors were largely
unsuccessful, and we did not receive a reason to explain the difference
in response rates between the two reviews. This ﬁnding underscores
the need for systemic change in how research ﬁndings are reported in
environmental health such as by adoption of the Animal Research:
Reporting of In Vivo Experiments (ARRIVE) and the Strengthening the
Reporting of Observational Studies in Epidemiology (STROBE) guide-
lines, in addition to reporting further information as we describe in
Vesterinen et al. (2013).
We did not downgrade the quality rating of the body of evidence
for publication bias because we had no direct evidence that it existed.
Because the body of literature on triclosan is relatively small, we were
unable to evaluate publication bias using the funnel plot method
typically used in systematic reviews in the healthcare ﬁeld. As such,
we cannot rule out that a publication bias exists.
As with our previous PFOA case study (Koustas et al., 2014) the ma-
jority of the included animal studies were “probably high risk of bias”,
particularly for the “allocation concealment” and “blinding” domains.
This “worrisome truth” about the conduct and reporting of experimental
animal studies in environmental health (Woodruff and Sutton, 2014) is
also prevalent in the preclinical literature, and introduces bias into study
ﬁndings (Bebarta et al., 2003; Landis et al., 2012; Macleod et al., 2004;
McPartland et al., 2007; van der Worp and Macleod, 2011; van der
Worp et al., 2007; Vesterinen et al., 2011; Holman et al., 2015).
There were other important limitations of some of the included
studies. For example, the paper by Axelstad et al. (2013) reports on
two separate experiments. One reasonably well-conducted experiment
exposed pregnant and lactating rats to triclosan, and evaluated thyrox-
ine levels in dams and their offspring. The second experiment involved
direct dosing of nursing pups with triclosan in a corn oil vehicle. As the
study authors point out, the results of the second experiment are com-
promised by genetic homogeneity among pups of the single surviving
control litter, as well as by the high thyroxine levels in this control litter
compared to their laboratory's historical controls. In addition, because
the studies by Paul et al. combined males and females, they may have
masked any sex-dependent differences in effect.
We designed our search to capture a wide range of outcomes by
using chemical terms only and not limiting the search with outcome
terms. This was an effective strategy because there were a relatively
small number of studies on triclosan. Developing our PECO question
and reference screening criteria was an undertaking that leveraged
the extensive knowledge of the scientists at the CalEPA Ofﬁce of Envi-
ronmental Health Hazard Assessment. Our experience in developing
these criteria points to the need for topic experts to be engaged in sys-
tematic reviews from the onset of the review.
Consistent with our previous case study (Koustas et al., 2014;
Johnson et al., 2014), we found it was efﬁcient to sort through a large
number of studies captured through our searchdue to predeﬁned exclu-
sion criteria (derived from the PECO statement) and the use of Distiller
software; on average it took approximately 15 s to screen each abstract
and eliminate the majority of irrelevant studies. Screening potentially
relevant full texts took on average 1.5 min per study.
While the efﬁciency and effectiveness of our screening methods ex-
pedited the review, the lack of tools to assess risk of bias for the diversity
of evidence streams retrieved, i.e., invertebrate studies, in vitro studies,
ﬁsh studies, and amphibian studies impeded inclusion of all of the rele-
vant data. We lacked the time, resources, and expertise to develop the
necessary assessment tools for the non-human non-mammalian evi-
dence streams in the one year we had allocated to complete this case
study. Hence, we were unable to include these studies in the review
as we had initially set out to do. Risk of bias assessment tools for
727P.I. Johnson et al. / Environment International 92–93 (2016) 716–728model systems in environmental health is a critical research and devel-
opment need in evidence integration. A critical requirement of evidence
integration in environmental health is that each stream of evidence,
i.e., human, non-human, mechanistic, etc., needs to be systematically
reviewed, including for risk of bias for individual studies, before this ev-
idence is integrated into the results. Future work will also look to estab-
lish precedents for efﬁcient systematic assessment for chemicals with
larger data sets, multiple inter-related endpoints that reﬂect disruption
of fundamental developmental or reproductive processes, supported by
a robust mechanistic literature.
In summary, we found that there was sufﬁcient non-human
evidence and inadequate human evidence of an association between
triclosan exposure and thyroxine concentrations, and that triclosan is
“possibly toxic” to reproductive and developmental health. Triclosan
has a relatively sparse data set, with few human studies. Our conclusion
was based on themost data rich endpoint, not necessarily themost sen-
sitive endpoint, and it excluded consideration of non-mammalian data
due to heterogeneity of these data and a corresponding lack of methods
for assessing the quality of these studies. Our conclusion that triclosan is
“possibly toxic” illustrates that current regulatory policies permit wide-
spread exposure to environmental chemicals in the absence of evidence
of safety.
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